A Phase I Study of TAS-114 in Healthy Adult Male Subjects

A Phase I, Randomized, Double-Blind, Placebo-Controlled Trial of Single and Multiple Doses of TAS-114 in Healthy Adult Male Subjects

Status

Unknown

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080221521

Enrollment

Registered

2011-07-25

Start date

2011-07-25

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Adult Male Subjects

Interventions

investigational material(s) Generic name etc : TAS-114 INN of investigational material : Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: - Healthy male subject who have given written informed consent - Subject's age of twenty years old or more and less than forty years old - Subject's weight of 50.0kg or more and BMI (Body Mass Index) of 18.0-25.0kg/m2

Exclusion criteria

Exclusion criteria: - Subject with a history or concurrent status of allergic reaction - Subject with a history or concurrent status of alcoholic or drug addiction - Subject who is not willing to stop smoking during hospitalization - Subject who recieved other investigational drug within 180 days before receiving the study drug

Design outcomes

Primary

Measure	Time frame
Safety, Pharmacokinetics CTCAE (ver.4.0)	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026